- Signaling Pathways
- Antibody-Drug Conjugate/ADC Related PROTAC
- PROTAC-Linker Conjugates for PAC
PROTAC-Linker Conjugates for PAC
PROTAC-Linker for PROTAC-antibody Conjugates
PROTAC-linker Conjugate for PAC comprises an antibody conjugated via a linker to a PROTAC. The PROTAC-Antibody Conjugate (PAC) molecules comprise an antibody conjugated via a linker (L1) to a PROTAC, wherein the PROTAC comprises an ubiquitin E3 ligase binding groug (“E3LB”), a linker (“L2”) and a protein binding group (“PB”). To obtain a PAC having potent efficacy and a desirable therapeutic index, the following components are provided. 1. Antibody (Ab): The antibody portion of a PAC can target a cell that expresses an antigen whereby the antigen specific PAC is delivered intracellularly to the target cell, typically through endocytosis While PACs that comprise an antibody directed to an antigen that is not found on the cell surface may result in less specific intracellular delivery of the PROTAC portion into the cell, the PAC may still undergo pinocytosis. 2. Linkers (L1): A“linker” (L1) is a bifunctional or multifunctional moiety that can be used to link one or more PROTAC moieties (D) to an antibody (Ab) to form a PAC. In some embodiments, PACs can be prepared using a L1 having reactive functionalities for covalently attaching to the PROTAC and to the antibody. 3. PROTAC(D).
-
PROTAC-Linker Conjugates for PAC Related Products (14)
- 1
-
MC-(β-Ala)-PABC-(β-D-GlcUA)-amide-PEG1-CH2-CC-885
0 ImagesMC-(β-Ala)-PABC-(β-D-GlcUA)-amide-PEG1-CH2-CC-885 (Compound Ie) is a neodegrader conjugate, can be used in the synthesis of antibody neoDegrader conjugate (AnDC). -
loading...Please select quantityGet Quote
August 31
-
Please select quantity
August 31
Get Quote
loading... -
-
PROTAC BRD4 Degrader-5-CO-PEG3-N3
0 ImagesPROTAC BRD4 Degrader-5-CO-PEG3-N3 is a PROTAC-linker Conjugate for PAC, comprises the BRD4 degrader (MZ 1 (HY-107425) analog) and PEG-based linker. PROTAC BRD4 Degrader-5-CO-PEG3-N3 is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups. PROTAC BRD4 Degrader-5-CO-PEG3-N3 can be used for the research of HER2-positive breast cancer. -
loading...Please select quantityGet Quote
August 31
-
Please select quantity
August 31
Get Quote
loading... -
- MC-Val-Cit-PAB-PROTAC ERα Degrader-1
-
loading...Please select quantityGet Quote
August 31
-
Please select quantity
August 31
Get Quote
loading... -
-
GNE-987 GSH linker-1
0 ImagesGNE-987 GSH linker-1, a PROTAC-linker Conjugate for PAC, comprises the chimeric BET degrader GNE-987 (HY-129937A) and disulfide-containing linker. GNE-987 GSH linker-1 remains inactive as a degrader until intracellular release of GNE-987 via disulfide reduction and linker self-immolation. GNE-987 GSH linker-1 can be used for the research of acute myeloid leukemia. -
loading...Please select quantityGet Quote
August 31
-
Please select quantity
August 31
Get Quote
loading... -
-
Mal-PEG1-Val-Cit-PABC-diphosphate-BTK degrader-1
0 ImagesCat. No.: HY-157763Mal-PEG1-Val-Cit-PABC-diphosphate-BTK degrader-1 is a cleavable linker-payload conjugate and cereblon-binding BTK bifunctional degrader. Mal-PEG1-Val-Cit-PABC-diphosphate-BTK degrader-1 induces BTK degradation and exerts cytotoxic effects when delivered via CD79b monoclonal antibody. Mal-PEG1-Val-Cit-PABC-diphosphate-BTK degrader-1, when formulated as a CD79b antibody-drug conjugate, achieves sustained in vivo BTK degradation in tumor-bearing mice with reduced systemic payload exposure. Mal-PEG1-Val-Cit-PABC-diphosphate-BTK degrader-1 can be used for the research of activated b-cell-like diffuse large b-cell lymphoma (ADC linker: (HY-130944); PROTAC: (HY-163295)). -
loading...Please select quantityGet Quote
August 31
-
Please select quantity
August 31
Get Quote
loading... -
-
L1-CIDE-BRM1-13
0 ImagesCat. No.: HY-183939CAS No.: 2760138-46-1L1-CIDE-BRM1-13 (Compound 15) is a linker-drug precursor moiety formed by the covalent conjugation of a PROTAC degrader with a linker for degrader-antibody conjugates (DACs). L1-CIDE-BRM1-13 can be used for the synthesis of DACs. -
loading...Please select quantityGet Quote
August 31
-
Please select quantity
August 31
Get Quote
loading... -
-
KVL-9
0 ImagesCat. No.: HY-186226CAS No.: 3113309-33-1KVL-9 is an intermediate used for constructing KRAS degrading antibody conjugates (DACs). KVL-9 consists of a KRAS small molecule binder, spacer, VHL recruitment ligand, and a cleavable antibody linker. KVL-9 achieves antigen-dependent intracellular delivery and induces ubiquitin-proteasome degradation of the KRAS protein mediated by VHL by conjugating with tumor antigen-targeting antibodies. -
loading...Please select quantityGet Quote
August 31
-
Please select quantity
August 31
Get Quote
loading... -
-
PROTAC BRD4 Degrader linker conjugate-1
0 ImagesPROTAC BRD4 Degrader linker conjugate is a linker-payload conjugate as well as a bifunctional degrader of BRD4 that binds to VHL, consisting of PROTAC and a linker. PROTAC BRD4 Degrader linker conjugate can be conjugated with STEAP1 and CLL1 antibodies to degrade BRD4 protein, with DC50 values of 0.86 nM and 7.6 nM, respectively. PROTAC BRD4 Degrader linker conjugate can be used in research related to prostate cancer and acute myeloid leukemia (BRD4 ligand: (HY-129939); VHL ligand: (HY-125845)).\n -
loading...Please select quantityGet Quote
August 31
-
Please select quantity
August 31
Get Quote
loading... -
-
cBu-Cit-GAL-02-221
0 ImagesCat. No.: HY-160694CAS No.: 2417369-73-2Synonyms: cBu-Cit-PROTAC BRD4 Degrader-5cBu-Cit-GAL-02-221 is a PROTAC that degrades BRD4 by association with cBu-Cit. cBu-Cit-GAL-02-221 can effectively inhibit BRD4 in HER2 positive and negative breast cancer cell lines. cBu-Cit-GAL-02-221 has a single bond and can be conjugated to an ADC antibody to form a PAC. -
loading...Please select quantityGet Quote
August 31
-
Please select quantity
August 31
Get Quote
loading... -
-
PROTAC ER Degrader-3
0 ImagesCat. No.: HY-128527CAS No.: 2158322-29-1PROTAC ER Degrader-3 is an intermediate for synthesis of PAC. PAC, consists the ADCs linker and PROTACs, conjugated to an antibody. PAC extracts from patent WO2017201449A1, compound LP2. PAC conjugated to an antibody is a more marked estrogen receptor-alpha (ERα) degrader compared to PROTAC (without Ab). -
loading...Please select quantityGet Quote
August 31
-
Please select quantity
August 31
Get Quote
loading... -
- (S)-Deoxy-thalidomide-2,7-diazaspiro[3.5]nonane-CH2-Me-PIP-Boc
-
loading...Please select quantityGet Quote
August 31
-
Please select quantity
August 31
Get Quote
loading... -
-
E3 Ligase Ligand-linker Conjugate 214
0 ImagesCat. No.: HY-179230CAS No.: 2451247-91-7 -
loading...Please select quantityGet Quote
August 31
-
Please select quantity
August 31
Get Quote
loading... -
- Nrf2 ligand-Linker Conjugate 2
-
loading...Please select quantityGet Quote
August 31
-
Please select quantity
August 31
Get Quote
loading... -
-
PROTAC ER Degrader-2
0 ImagesCat. No.: HY-128528PROTAC ER Degrader-2 is an intermediate for synthesis of PAC. PAC, consists the ADCs linker and PROTACs, conjugated to an antibody. PAC extracts from patent WO2017201449A1, compound LP2. PAC conjugated to an antibody is a more marked estrogen receptor-alpha (ERα) degrader compared to PROTAC (without Ab). -
loading...Please select quantityGet Quote
August 31
-
Please select quantity
August 31
Get Quote
loading... -
- 1